Tezepelumab Reduces Patient-reported Cough and Phlegm Production in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study

被引：0

作者：

Castro, M. ^{[1
]}

Kraft, M. ^{[2
]}

Ambrose, C. S. ^{[3
]}

Martin, N. ^{[4
,5
]}

Clarke, N. ^{[6
]}

Spahn, J. D. ^{[7
]}

Llanos, J. ^{[8
]}

Ponnarambil, S. ^{[9
]}

机构：

[1] Univ Kansas, Div Pulm Crit Care & Sleep Med, Kansas City, KS USA

[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA

[3] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[4] AstraZeneca, BioPharmaceut R&D, Biometr Late Stage Dev Resp & Immunol, Waltham, MA USA

[5] Cytel, Waltham, MA USA

[6] AstraZeneca, Patient Ctr Sci Resp & Immunol, Gaithersburg, MD USA

[7] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Wilmington, DE USA

[8] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[9] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Cambridge, England

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A4752

引用

页数：2